. Author manuscript; available in PMC: 2014 Sep 11.

Published in final edited form as: Cochrane Database Syst Rev. 2010 Nov 10;(11):CD008040. doi: 10.1002/14651858.CD008040.pub2

Appendix 7. Associated symptoms: persistence 2 hours after treatment.

Associated symptoms: symptom present 2 hours after taking study medication
Intervention	Studies	Attacks treated	Treatment (%)	Placebo (%)	Relative risk (95% CI)	NNTp (95% CI)
Nausea
Paracetamol 1000 mg versus placebo (Freitag 2008; Hoernecke 1993; Prior 2010)	3	1004	22	33	0.67 (0.55 to 0.82)	9.2 (6.1 to 19)
Paracetamol 1000 mg versus placebo (Freitag 2008; Prior 2010) for moderate to severe pain	2	428	30	43	0.69 (0.54 to 0.89)	7.6 (4.5 to 24)
Paracetamol 1000 mg versus dihydroergotamine 2 mg (Hoernecke 1993)	1	576	17	19	-	-
Paracetamol + domperidone 1000 + 20 mg (Dowson 2000)	1	240	37	39	-	-
Paracetamol + metoclopramide 1000 + 10 mg (GSK1)	1	574	17	18	-	-
Photophobia
Paracetamol 1000 mg versus placebo (Freitag 2008; Hoernecke 1993; Lipton 2000; Prior 2010)	4	1292	50	57	0.86 (0.79 to 0.94)	14 (7.8 to 52)
Paracetamol 1000 mg versus placebo (Freitag 2008; Lipton 2000; Prior 2010) for moderate to severe pain	3	716	71	77	0.92 (0.85 to 1.0)	not calculated
Paracetamol 1000 mg versus dihydroergotamine 2 mg (Hoernecke 1993)	1	576	23	30
Phonophobia
Paracetamol 1000 mg versus placebo (Freitag 2008; Hoernecke 1993; Lipton 2000; Prior 2010)	4	1292	46	55	0.83 (0.75 to 0.91)	11 (7.0 to 29)
Paracetamol 1000 mg versus placebo (Freitag 2008; Lipton 2000; Prior 2010) for moderate to severe pain	3	716	66	75	0.88 (0.80 to 0.97)	11 (6.4 to 42)
Paracetamol 1000 mg versus dihydroergotamine 2 mg (Hoernecke 1993)	1	576	20	26	-	-
Combined “light/noise sensitivity”
Paracetamol + metoclopramide 1000 + 10 mg versus sumatriptan 100 mg (1st attack, GL/MIG/001/92; GL/MIG/001A/92)	2	1243	55	54	1.0 (0.92 to 1.1)	not calculated
Paracetamol + metoclopramide 1000 + 10 mg versus sumatriptan 100 mg (all 3 attacks, GL/MIG/001/92; GL/MIG/001A/92)	2	3274	57	52	1.1 (1.02 to 1.2)	20 (12 to 65)